The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
Open accessAbstract
The peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcriptional factor that belongs to the nuclear hormone receptor superfamily. PPARγ was initially identified through its role in the regulation of glucose and lipid metabolism and cell differentiation. It also influences the expression or activity of a number of genes in a variety of signalling networks. These include regulation of redox balance, fatty acid oxidation, immune responses and mitochondrial function. Recent studies suggest that the PPARγ agonists may serve as good candidates for the treatment of several neurodegenerative disorders including Parkinson's disease (PD), Alzheimer's disease, Huntington's disease and amyotrophic lateral sclerosis, even though multiple etiological factors contribute to the development of these disorders. Recent reports have also signposted a role for PPARγ coactivator-1α (PGC-1α) in several neurodegenerative disorders including PD. In this review, we explore the current knowledge of mechanisms underlying the beneficial effects of PPARγ agonists and PGC-1α in models of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“Drugs such as resveratrol, can act by decreasing PGC-1a acetylation, producing a subsequent increase in PGC-1a activity and its downstream genes [89].”
BackgroundSt-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607 · cited 1×
“In response to oxidative stress, Nrf2 translocates to the nucleus and dimerizes with another member of the Cap’n’Collar/basic leucine zipper family of transcription factors [69], activating transcription by binding to an antioxidant response element (ARE) located in the promoter of a number of antioxidant genes, inclu…”
BackgroundTelomere dysfunction induces metabolic and mitochondrial compromise
Sahin, E., Colla, S., Liesa, M., Moslehi, J., Müller, F. L., Guo, M., Cooper, M., Kotton, D., Fabian, A. J., Walkey, C., et al. (2011) · Nature · doi:10.1038/nature09787 · Cited by 1,319 · cited 1×
“It has been reported that PGC-1a expression is decreased with aging, possibly owing to decreased sirtuin1 (SIRT1) levels [85] or by the action of p53 that is activated by telomere shortening and suppresses PGC-1a [88].”
BackgroundLehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“Naturally occurring PPARc ligands include long chain fatty acids, other natural lipid ligands, eicosanoids and the prostaglandin 15d-PGJ2, but also few nonsteroidal antiinflammatory drugs, as ibuprofen, fenoprofen, and indomethacin A [15–17].”
BackgroundPARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Cited by
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Elfawy, H. A., & Das, B. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.029 · Cited by 343
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders
Jęśko, H., Wencel, P., Strosznajder, R. P., & Strosznajder, J. B. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2110-y · Cited by 259
Metadata
- Authors
- Corona, J. C., & Duchen, M. R.
- Venue
- Neurochemical Research
- Published
- 2014-07-10
- Volume
- 40
- Issue
- 2
- Pages
- 308-316
- ISSN
- 0364-3190 (ISSN-L)
- 1573-6903
- OpenAlex
- W1968448866
- Cited by
- 170
- References
- 15
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s. https://app.cochat.ai/papers/10.1007/s11064-014-1377-0
- The paper
- Corona, J. C., & Duchen, M. R. (2015). PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s. Neurochemical Research. https://doi.org/10.1007/s11064-014-1377-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.